Amgen vs. Accord Biopharma: Denosumab Biosimilar Patent Case Transferred to New Jersey

Case Overview

In a significant procedural development within the crowded biosimilar patent litigation landscape, Amgen, Inc. filed suit against Accord Biopharma, Inc. in the Eastern District of North Carolina on November 13, 2024, alleging patent infringement related to biosimilar versions of its blockbuster denosumab products—Prolia and XGEVA. Within just 93 days, the case was resolved at the district level—not on the merits, but through a transfer order consolidating it with parallel proceedings in the District of New Jersey under Judge Christine P. O’Hearn.

This case, docketed as 5:24-cv-00642, reflects a broader coordinated litigation strategy that Amgen has deployed against multiple biosimilar entrants challenging its denosumab franchise. For patent attorneys, IP professionals, and R&D teams operating in the biologics space, understanding the procedural mechanics and strategic implications of this transfer is essential intelligence in an increasingly complex biosimilar patent battleground.

The Parties

The Products at Issue

The accused products are biosimilar versions of Amgen’s denosumab drug products—specifically, biosimilar equivalents of Prolia and XGEVA. Denosumab is a fully human monoclonal antibody targeting RANK Ligand (RANKL), used to treat bone-related conditions. Commercial stakes are substantial; Prolia and XGEVA together generated over $5 billion in annual revenue for Amgen in recent years.

Legal Representation

Plaintiff Amgen assembled a formidable legal team spanning multiple prominent firms: Sidley Austin LLP, Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, and Maccord Mason PLLC, with lead attorneys including Jeffrey P. Kushan, Steven J. Horowitz, and Joshua J. Fougere—lawyers with deep biosimilar litigation experience.

Defendant Accord Biopharma was represented by Coats & Bennett, PLLC and McAndrews, Held & Malloy, Ltd., with counsel including Alejandro Menchaca and David E. Bennett, both experienced IP litigators in the pharmaceutical space.

Litigation Timeline & Procedural History

The case was filed on November 13, 2024, in the Eastern District of North Carolina—a venue choice likely connected to Accord Biopharma’s registered presence or operational activities in that jurisdiction. The BPCIA litigation framework often triggers multi-front filings as originator biologics companies pursue parallel actions against several biosimilar applicants simultaneously.

The case closed at the first-instance level on February 14, 2025, after only 93 days—an unusually short duration for patent infringement litigation, reflecting that no substantive merits proceedings occurred in North Carolina. The swift resolution was procedural: the court issued a transfer order consolidating this action with parallel denosumab biosimilar cases already pending in the District of New Jersey, assigned to Judge Christine P. O’Hearn for coordinated or consolidated pretrial proceedings. No specific basis of termination beyond the transfer was recorded in the case docket.

The Verdict & Legal Analysis

Outcome

The Eastern District of North Carolina ordered case transfer to the District of New Jersey pursuant to a multi-district litigation (MDL)-style coordination mechanism. The specific transfer order states:

“IT IS THEREFORE ORDERED that the actions listed on Schedule A and pending outside the District of New Jersey are transferred to the District of New Jersey and, with the consent of that court, assigned to the Honorable Christine P. O’Hearn for coordinated or consolidated pretrial proceedings.”

No damages were awarded, no injunction was granted or denied, and no merits ruling on patent validity or infringement was issued in this venue. The case’s closure in North Carolina is purely administrative—the substantive litigation will proceed in New Jersey.

Verdict Cause Analysis

The operative legal event is consolidation for pretrial coordination, a procedural mechanism used when multiple related cases presenting common factual and legal questions are pending in different districts. In the BPCIA context, originator companies like Amgen frequently file simultaneous infringement actions against multiple biosimilar applicants as each files an Abbreviated Biologics License Application (aBLA) with the FDA. When these cases proliferate across districts, consolidation before a single judge promotes judicial efficiency, prevents inconsistent claim constructions, and streamlines discovery on shared patent validity and infringement questions.

The transfer to Judge O’Hearn in New Jersey is significant. New Jersey’s District Court has emerged as a premier venue for pharmaceutical patent litigation, benefiting from judges with deep experience in Hatch-Waxman and BPCIA disputes. Consolidated pretrial proceedings mean that claim construction rulings, expert designations, and discovery protocols developed in the lead New Jersey cases will govern this action as well.

Legal Significance

This case exemplifies the coordinated multi-defendant BPCIA litigation strategy: by filing against multiple biosimilar applicants in different jurisdictions and then consolidating, originator companies achieve leverage through the sheer cost and complexity imposed on each defendant. For denosumab specifically, Amgen has pursued biosimilar challengers across multiple fronts, and this North Carolina filing against Accord is one node in a broader litigation network.

The transfer order, while procedurally routine, carries strategic weight: it subjects Accord Biopharma to consolidated proceedings where Amgen’s cumulative evidence, expert reports, and legal arguments developed against other denosumab biosimilar defendants may create compounding pressure.

Specific patent numbers were not disclosed in the available case record. IP professionals should monitor the consolidated New Jersey docket for patent identification and claim construction developments.

Strategic Takeaways

For Patent Holders (Originators):

• Coordinated multi-district filing followed by consolidation is an effective strategy to centralize denosumab—and by extension, complex biologics—patent disputes before experienced pharmaceutical patent judges.
• Selecting New Jersey as the consolidation hub leverages that district’s judicial familiarity with biologics patent law.

For Accused Infringers (Biosimilar Developers):

• Early jurisdictional analysis is critical; contesting venue before consolidation may be a viable defensive tactic.
• Consolidated proceedings require robust, early investment in shared invalidity and non-infringement positions across co-defendants.

For R&D Teams:

• Freedom-to-operate (FTO) analyses for denosumab biosimilars must account for Amgen’s layered patent portfolio—not just the composition-of-matter patents but also method-of-treatment, formulation, and manufacturing claims that may be asserted in consolidated proceedings.

Industry & Competitive Implications

The Amgen v. Accord Biopharma transfer reflects an accelerating trend in biosimilar patent litigation consolidation. As the U.S. biosimilar market matures—driven by the BPCIA’s regulatory framework and increasing FDA approvals—originator companies are refining coordinated IP enforcement strategies designed to delay market entry and maximize licensing leverage.

For the denosumab market specifically, multiple biosimilar developers are navigating Amgen’s patent estate simultaneously. Consolidation before a single federal judge creates a de facto industry-wide adjudication of denosumab patent validity and claim scope—outcomes that will bind or strongly influence all participants.

From a competitive intelligence standpoint, companies developing monoclonal antibody biosimilars should closely track the consolidated New Jersey proceedings. Claim construction rulings on denosumab patents will have direct downstream relevance to their own FTO positions and regulatory timelines.

The broader implication for the biologics industry: originator IP strategy increasingly weaponizes procedural coordination, making early legal counsel engagement—at the pre-aBLA filing stage—essential for biosimilar developers seeking to manage litigation risk and preserve market entry timelines.